CD28-ARS2 Axis Drives Metabolic Flexibility in CD8+ T Cells via PKM Alternative Splicing

Study Background and Research Question

Metabolic reprogramming is central to the functional capacity of T lymphocytes, particularly CD8+ T cells, which mediate cytotoxic immune responses against cancer. Upon antigen encounter, these cells undergo rapid bioenergetic shifts to support proliferation and effector functions, such as interferon gamma (IFNγ) production. While the induction of glycolysis through receptor-mediated pathways is well documented, the precise molecular mechanisms that confer metabolic flexibility on activated CD8+ T cells remain incompletely defined. The reference study investigates how posttranscriptional regulation—especially alternative splicing—modulates key glycolytic enzymes to support T cell antitumor activity.

Key Innovation from the Reference Study

The pivotal discovery is the identification of a novel signaling axis in which CD28 costimulation leads to upregulation of ARS2, a nuclear cap-binding complex adaptor protein. This CD28-ARS2 axis orchestrates alternative splicing of pre-mRNAs during T cell activation, with a pronounced effect on the pyruvate kinase M (PKM) gene. Specifically, ARS2 activity suppresses the PKM1 isoform in favor of PKM2—an isoform known for its role in tumor metabolism and now shown to be critical for the metabolic plasticity of CD8+ T cells. This splicing control is independent of the canonical PI3K pathway, revealing a previously unappreciated layer of metabolic regulation in immune cells.

Methods and Experimental Design Insights

The research team employed a combination of genetic, transcriptomic, and metabolic analyses in murine CD8+ T cell models. CD8+ T cells were activated in vitro under defined stimulation conditions to dissect the contributions of CD28 and ARS2. RNA sequencing was used to profile activation-induced alternative splicing, while specific knockout and overexpression models clarified ARS2's role. Functional assays assessed cytokine production, cytotoxicity, and metabolic flux, with a focus on glycolytic and oxidative pathways. The researchers also distinguished the splicing effects of CD28-ARS2 from those of the PI3K signaling branch, allowing for mechanistic separation of these two costimulatory outputs.

Core Findings and Why They Matter

Activation of CD8+ T cells through CD28 signaling robustly upregulated ARS2, which in turn recruited splicing factors to pre-mRNAs and altered roughly one-third of alternative splicing events triggered by T cell stimulation. Of particular importance, the ARS2-dependent shift in PKM splicing favored PKM2 over PKM1. Functionally, PKM2 expression correlated with enhanced glucose utilization, increased production of IFNγ, and superior antitumor effector functions. These effects were shown to be independent of the CD28-PI3K axis, indicating that distinct CD28 outputs separately control metabolic transporter expression and glycolytic enzyme splicing. The study thus positions posttranscriptional control of glycolytic enzymes—including PKM—as a central determinant of immunometabolic competence in cytotoxic T cells (reference).

This insight is particularly meaningful for the development of immunotherapeutic strategies, as it reveals that targeting alternative splicing or its upstream regulators could enhance CD8+ T cell responses in cancer. The metabolic flexibility endowed by PKM2 supports not only effector cytokine production but also robust proliferative and cytotoxic functions, potentially improving outcomes in adoptive T cell therapies or checkpoint blockade regimens.

Comparison with Existing Internal Articles

Several internal resources contextualize these findings within broader research on metabolic reprogramming and multidrug resistance. For example, an internal article recapitulates the reference study's central thesis, highlighting the role of the CD28-ARS2 axis in coordinating PKM splicing and metabolic plasticity. Another perspective draws links between transporter biology, immunometabolism, and multidrug resistance, proposing that interventions targeting metabolic pathways—including MRP inhibitors such as Probenecid—could modulate similar axes of immune cell function. Additionally, reviews such as this article discuss the interface between metabolic flexibility in immune cells and pharmacological modulation via transporter inhibitors, including their potential impact on neuroprotection and multidrug resistance reversal in leukemia.

Together, these resources underscore the translational relevance of modulating both metabolic enzymes (e.g., PKM2) and transporters (e.g., MRPs) in the context of immunotherapy and chemoresistance.

Limitations and Transferability

While the findings provide significant mechanistic insights, some limitations should be considered. The bulk of the experimental work relies on murine models and in vitro systems, which, while highly informative, may not fully recapitulate the complexity of human T cell responses in vivo. The precise regulatory elements and splicing factors involved downstream of ARS2 remain to be elucidated, and the potential crosstalk with other metabolic and signaling pathways in the tumor microenvironment warrants further investigation. Additionally, whether pharmacological manipulation of this axis—such as through splicing modulators or transporter inhibitors—can be safely and effectively leveraged in clinical settings remains to be determined.

Protocol Parameters

• CD8+ T cell activation: Stimulate purified murine CD8+ T cells with anti-CD3 and anti-CD28 antibodies (e.g., 1-2 μg/mL) for 24-72 hours to induce metabolic reprogramming and alternative splicing events.
• ARS2 modulation: Use genetic knockout or overexpression systems (e.g., lentiviral vectors) to dissect the role of ARS2 in alternative splicing during T cell activation.
• PKM splicing analysis: Employ RT-PCR or targeted RNA sequencing to quantify PKM1 and PKM2 isoform expression post-activation.
• Functional assessment: Measure IFNγ, TNFα, and IL-2 production via ELISA or flow cytometry; evaluate cytotoxicity using standard killing assays.
• Metabolic profiling: Use extracellular flux analysis (e.g., Seahorse) to assess glycolytic and oxidative phosphorylation capacity.
• Workflow suggestion: Consider integrating transporter inhibition (e.g., with Probenecid) to explore multidrug resistance reversal or modulation of immune cell metabolic states, referencing established dosing and handling protocols.

Research Support Resources

Researchers aiming to explore the intersection of metabolic reprogramming and multidrug resistance in immune cells may find value in validated inhibitors such as Probenecid (4-(dipropylsulfamoyl)benzoic acid, SKU B2014). As a well-characterized inhibitor of organic anion transporters and multidrug resistance-associated proteins, Probenecid has been employed in studies of multidrug resistance reversal in leukemia and neuroprotection in cerebral ischemia/reperfusion injury. APExBIO supplies research-grade Probenecid suitable for integration into immunometabolic and transporter modulation workflows.